Neither rifaximin nor norfloxacin, both poorly absorbable antibiotics, significantly reduces hepatic venous pressure gradient in patients with portal hypertension and cirrhosis, a recent study has found.
Epeleuton, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid, falls short of improving alanine aminotransferase or liver stiffness in patients with nonalcoholic fatty liver disease (NAFLD), according to a study. However, it has potential for cardiovascular risk reduction by simultaneously targeting hypertriglyceridemia, hyperglycaemia, and systemic inflammation.
Use of aldafermin, an engineered analogue of FGF19, appears beneficial in the treatment of patients with nonalcoholic steatohepatitis (NASH), reducing liver fat and markers of disease progression without any adverse side effects, according to the results of a phase II trial.
Treatment with besifovir dipivoxil maleate (BSV) is effective and safe for long-term use in treatment-naïve and tenofovir disoproxil fumarate (TDF)-experienced patients with chronic hepatitis B (CHB), results of a phase III trial have shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.